COVID-19 symptom severity among smokers: Insights from a direct-to-community registry
Nancy A Dreyer(IQVIA (United Kingdom)), Matthew W. Reynolds(IQVIA (United States)), Emma Brinkley(IQVIA (United States)), Natalia Petruski‐Ivleva(AVEO Oncology (United States)), Christina Mack(University of North Carolina at Chapel Hill), Lisa Albert(IQVIA (United States))
Pharmacoepidemiology and Drug Safety
January 1, 2021
Cited by 0
Related Papers
Dietary Protein Sources and Risk for Incident Chronic Kidney Disease: Results From the Atherosclerosis Risk in Communities (ARIC) Study
|Journal of Renal Nutrition|2017|254
Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies
|PLoS Biology|2021|215
Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms
|Pharmacoepidemiology and Drug Safety|2020|120
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
|Annals of the Rheumatic Diseases|2023|95
Methods for external control groups for single arm trials or <scp>long‐term</scp> uncontrolled extensions to randomized clinical trials
|Pharmacoepidemiology and Drug Safety|2020|68